174 related articles for article (PubMed ID: 35794555)
1. Syringin exerts anti-breast cancer effects through PI3K-AKT and EGFR-RAS-RAF pathways.
Wang F; Yuan C; Liu B; Yang YF; Wu HZ
J Transl Med; 2022 Jul; 20(1):310. PubMed ID: 35794555
[TBL] [Abstract][Full Text] [Related]
2. Syringin prevents bone loss in ovariectomized mice via TRAF6 mediated inhibition of NF-κB and stimulation of PI3K/AKT.
Liu J; Zhang Z; Guo Q; Dong Y; Zhao Q; Ma X
Phytomedicine; 2018 Mar; 42():43-50. PubMed ID: 29655696
[TBL] [Abstract][Full Text] [Related]
3. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
[TBL] [Abstract][Full Text] [Related]
4. Anti-breast-Cancer Activity Exerted by β-Sitosterol-d-glucoside from Sweet Potato via Upregulation of MicroRNA-10a and via the PI3K-Akt Signaling Pathway.
Xu H; Li Y; Han B; Li Z; Wang B; Jiang P; Zhang J; Ma W; Zhou D; Li X; Ye X
J Agric Food Chem; 2018 Sep; 66(37):9704-9718. PubMed ID: 30160115
[TBL] [Abstract][Full Text] [Related]
5. Hsa_circ_001569 is an unfavorable prognostic factor and promotes cell proliferation and metastasis by modulating PI3K-AKT pathway in breast cancer.
Xu JH; Wang Y; Xu D
Cancer Biomark; 2019; 25(2):193-201. PubMed ID: 31104012
[TBL] [Abstract][Full Text] [Related]
6. Function of miR-152 as a Tumor Suppressor in Human Breast Cancer by Targeting PIK3CA.
Ge S; Wang D; Kong Q; Gao W; Sun J
Oncol Res; 2017 Sep; 25(8):1363-1371. PubMed ID: 28247844
[TBL] [Abstract][Full Text] [Related]
7. Tumor suppressive activity of miR-424-5p in breast cancer cells through targeting PD-L1 and modulating PTEN/PI3K/AKT/mTOR signaling pathway.
Dastmalchi N; Hosseinpourfeizi MA; Khojasteh SMB; Baradaran B; Safaralizadeh R
Life Sci; 2020 Oct; 259():118239. PubMed ID: 32784058
[TBL] [Abstract][Full Text] [Related]
8. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.
Sabine VS; Crozier C; Brookes CL; Drake C; Piper T; van de Velde CJ; Hasenburg A; Kieback DG; Markopoulos C; Dirix L; Seynaeve C; Rea DW; Bartlett JM
J Clin Oncol; 2014 Sep; 32(27):2951-8. PubMed ID: 25071141
[TBL] [Abstract][Full Text] [Related]
9. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
[TBL] [Abstract][Full Text] [Related]
10. Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer.
Young CD; Zimmerman LJ; Hoshino D; Formisano L; Hanker AB; Gatza ML; Morrison MM; Moore PD; Whitwell CA; Dave B; Stricker T; Bhola NE; Silva GO; Patel P; Brantley-Sieders DM; Levin M; Horiates M; Palma NA; Wang K; Stephens PJ; Perou CM; Weaver AM; O'Shaughnessy JA; Chang JC; Park BH; Liebler DC; Cook RS; Arteaga CL
Mol Cell Proteomics; 2015 Jul; 14(7):1959-76. PubMed ID: 25953087
[TBL] [Abstract][Full Text] [Related]
11. Suppression of SPIN1-mediated PI3K-Akt pathway by miR-489 increases chemosensitivity in breast cancer.
Chen X; Wang YW; Xing AY; Xiang S; Shi DB; Liu L; Li YX; Gao P
J Pathol; 2016 Aug; 239(4):459-72. PubMed ID: 27171498
[TBL] [Abstract][Full Text] [Related]
12. S-equol inhibits proliferation and promotes apoptosis of human breast cancer MCF-7 cells via regulating miR-10a-5p and PI3K/AKT pathway.
Zhang J; Ren L; Yu M; Liu X; Ma W; Huang L; Li X; Ye X
Arch Biochem Biophys; 2019 Sep; 672():108064. PubMed ID: 31390527
[TBL] [Abstract][Full Text] [Related]
13. A novel hydrogen sulfide-releasing donor, HA-ADT, suppresses the growth of human breast cancer cells through inhibiting the PI3K/AKT/mTOR and Ras/Raf/MEK/ERK signaling pathways.
Dong Q; Yang B; Han JG; Zhang MM; Liu W; Zhang X; Yu HL; Liu ZG; Zhang SH; Li T; Wu DD; Ji XY; Duan SF
Cancer Lett; 2019 Jul; 455():60-72. PubMed ID: 31042588
[TBL] [Abstract][Full Text] [Related]
14. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
[TBL] [Abstract][Full Text] [Related]
15. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
16. Syringin Prevents Aβ
Zhang N; Zhao L; Su Y; Liu X; Zhang F; Gao Y
Neurochem Res; 2021 Mar; 46(3):675-685. PubMed ID: 33471295
[TBL] [Abstract][Full Text] [Related]
17. Ethanol Extracts of Dietary Herb,
Kuo CY; Weng TS; Kumar KJS; Tseng YH; Tung TW; Wang SY; Wang HC
Integr Cancer Ther; 2019; 18():1534735419866924. PubMed ID: 31409145
[TBL] [Abstract][Full Text] [Related]
18. Tanshinone IIA can inhibit MiaPaCa‑2 human pancreatic cancer cells by dual blockade of the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways.
Su CC
Oncol Rep; 2018 Nov; 40(5):3102-3111. PubMed ID: 30226540
[TBL] [Abstract][Full Text] [Related]
19. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
Saini KS; Loi S; de Azambuja E; Metzger-Filho O; Saini ML; Ignatiadis M; Dancey JE; Piccart-Gebhart MJ
Cancer Treat Rev; 2013 Dec; 39(8):935-46. PubMed ID: 23643661
[TBL] [Abstract][Full Text] [Related]
20. Oxypalmatine regulates proliferation and apoptosis of breast cancer cells by inhibiting PI3K/AKT signaling and its efficacy against breast cancer organoids.
Lin X; Chen D; Chu X; Luo L; Liu Z; Chen J
Phytomedicine; 2023 Jun; 114():154752. PubMed ID: 36948141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
